product summary
Loading...
company name :
R&D Systems
product type :
antibody
product name :
Cadherin-6/KCAD Antibody (09) [mFluor Violet 500 SE]
catalog :
NBP3-12779MFV500
quantity :
0.1 ml
price :
379 USD
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
09
reactivity :
human
application :
ELISA
more info or order :
product information
brand :
Novus
master code :
NBP3-12779MFV500
SKU :
NBP3-12779MFV500
product name :
Cadherin-6/KCAD Antibody (09) [mFluor Violet 500 SE]
sizes available :
0.1 ml
description :
The Cadherin-6/KCAD Antibody (09) [mFluor Violet 500 SE] from NBP3-12779MFV500 is a 6.7e-05 antibody to . This antibody reacts with human.
target :
Cadherin-6/KCAD
category :
Primary Antibodies
buffer :
50mM Sodium Borate
clonality :
Monoclonal
clone :
09
conjugate :
mFluor Violet 500 SE
all_available conjugate :
DyLight 755;Janelia Fluor 646;DyLight 550;Alexa Fluor 488;DyLight 594;mFluor Violet 500 SE
dilution :
ELISA
host :
Mouse
immunogen :
This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human Cadherin-6/KCAD (Accession#: NP_004923.1; Met1-Ala615).
isotype :
IgG1
purity :
Protein A purified
species :
Human
gene symbol :
CDH6
applications :
ELISA
USD :
379 USD
alt names :
cadherin 6, type 2, K-cadherin (fetal kidney), cadherin, fetal kidney, cadherin-6, KCAD, K-cadherin, K-cadherin (fetal kidney)
storage :
Store at 4C in the dark.
more info or order :
company information

R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.
related products
browse more products
questions and comments
